9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Potentiation of B2 receptor signaling by AltB2R, a newly identified alternative protein encoded in the human bradykinin B2 receptor gene

      research-article
      1 , 2 , 3 , 2 , 3 , 4 , 5 , 1 , 2 , , 3 , 2 ,
      The Journal of Biological Chemistry
      American Society for Biochemistry and Molecular Biology
      alternative open reading frames (AltORFs), coding DNA sequence (CDS), G-protein-coupled receptors (GPCRs), bradykinin (BK), B2 receptor (B2R), signal transduction, mitogen-activated protein kinases (MAPK), AltORFs, alternative open reading frames, BiFC, bimolecular fluorescence complementation, BK, bradykinin, CDC, coding DNA sequence, DAB, diaminobenzidine, DMEM, Dulbecco's modified Eagle's medium, EGFR, epidermal growth factor receptor, FBS, fetal bovine serum, GPCR, G-protein-coupled receptor, IF, immunofluorescence, IHC, immunohistochemistry, IP3, 1,4,5-inositol trisphosphate, KD, kallidin, MAPK, mitogen-activated protein kinases, PBS, phosphate-buffered saline, WB, western blot

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Recent functional and proteomic studies in eukaryotes ( www.openprot.org) predict the translation of alternative open reading frames (AltORFs) in mature G-protein-coupled receptor (GPCR) mRNAs, including that of bradykinin B2 receptor (B2R). Our main objective was to determine the implication of a newly discovered AltORF resulting protein, termed AltB2R, in the known signaling properties of B2R using complementary methodological approaches. When ectopically expressed in HeLa cells, AltB2R presented predominant punctate cytoplasmic/perinuclear distribution and apparent cointeraction with B2R at plasma and endosomal/vesicular membranes. The presence of AltB2R increases intracellular [Ca 2+] and ERK1/2-MAPK activation ( via phosphorylation) following B2R stimulation. Moreover, HEK293A cells expressing mutant B2R lacking concomitant expression of AltB2R displayed significantly decreased maximal responses in agonist-stimulated Gα q-Gα i2/3–protein coupling, IP 3 generation, and ERK1/2-MAPK activation as compared with wild-type controls. Conversely, there was no difference in cell-surface density as well as ligand-binding properties of B2R and in efficiencies of cognate agonists at promoting B2R internalization and β-arrestin 2 recruitment. Importantly, both AltB2R and B2R proteins were overexpressed in prostate and breast cancers, compared with their normal counterparts suggesting new associative roles of AltB2R in these diseases. Our study shows that BDKRB2 is a dual-coding gene and identifies AltB2R as a novel positive modulator of some B2R signaling pathways. More broadly, it also supports a new, unexpected alternative proteome for GPCRs, which opens new frontiers in fields of GPCR biology, diseases, and drug discovery.

          Related collections

          Most cited references59

          • Record: found
          • Abstract: found
          • Article: not found

          Trends in GPCR drug discovery: new agents, targets and indications

          G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, largely due to their substantial involvement in human pathophysiology and their pharmacological tractability. Here, we report the first analysis of all GPCR drugs and agents in clinical trials. This reveals the current trends across molecule types, drug targets and therapeutic indications, including showing that 481 drugs (~34% of all drugs approved by the FDA) act at 107 unique GPCR targets. Approximately 320 agents are currently in clinical trials, of which ~36% target 64 potentially novel GPCR targets without an approved drug, and the number of biological drugs, allosteric modulators and biased agonists has grown. The major disease indications for GPCR modulators show a shift towards diabetes, obesity, and Alzheimer’s disease, while other central nervous system disorders remain highly represented. The 227 (57%) non-olfactory GPCRs that are yet to be explored in clinical trials have broad untapped therapeutic potential, particularly in genetic and immune system disorders. Finally, we provide an interactive online resource to analyse and infer trends in GPCR drug discovery.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Proteogenomics: concepts, applications and computational strategies.

            Proteogenomics is an area of research at the interface of proteomics and genomics. In this approach, customized protein sequence databases generated using genomic and transcriptomic information are used to help identify novel peptides (not present in reference protein sequence databases) from mass spectrometry-based proteomic data; in turn, the proteomic data can be used to provide protein-level evidence of gene expression and to help refine gene models. In recent years, owing to the emergence of new sequencing technologies such as RNA-seq and dramatic improvements in the depth and throughput of mass spectrometry-based proteomics, the pace of proteogenomic research has greatly accelerated. Here I review the current state of proteogenomic methods and applications, including computational strategies for building and using customized protein sequence databases. I also draw attention to the challenge of false positive identifications in proteogenomics and provide guidelines for analyzing the data and reporting the results of proteogenomic studies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A micropeptide encoded by a putative long noncoding RNA regulates muscle performance.

              Functional micropeptides can be concealed within RNAs that appear to be noncoding. We discovered a conserved micropeptide, which we named myoregulin (MLN), encoded by a skeletal muscle-specific RNA annotated as a putative long noncoding RNA. MLN shares structural and functional similarity with phospholamban (PLN) and sarcolipin (SLN), which inhibit SERCA, the membrane pump that controls muscle relaxation by regulating Ca(2+) uptake into the sarcoplasmic reticulum (SR). MLN interacts directly with SERCA and impedes Ca(2+) uptake into the SR. In contrast to PLN and SLN, which are expressed in cardiac and slow skeletal muscle in mice, MLN is robustly expressed in all skeletal muscle. Genetic deletion of MLN in mice enhances Ca(2+) handling in skeletal muscle and improves exercise performance. These findings identify MLN as an important regulator of skeletal muscle physiology and highlight the possibility that additional micropeptides are encoded in the many RNAs currently annotated as noncoding. Copyright © 2015 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                Journal
                J Biol Chem
                J Biol Chem
                The Journal of Biological Chemistry
                American Society for Biochemistry and Molecular Biology
                0021-9258
                1083-351X
                23 January 2021
                2021
                23 January 2021
                : 296
                : 100329
                Affiliations
                [1 ]Department of Biochemistry, Université de Sherbrooke, Sherbrooke, Québec, Canada
                [2 ]Institute of Pharmacology, Université de Sherbrooke, Sherbrooke, Québec, Canada
                [3 ]Department of Pharmacology & Physiology, Université de Sherbrooke, Sherbrooke, Québec, Canada
                [4 ]Department of Immunology & Cellular Biology, Université de Sherbrooke, Sherbrooke, Québec, Canada
                [5 ]Department of Pathology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Québec, Canada
                Author notes
                []For correspondence: Xavier Roucou; Fernand Gobeil Xavier.Roucou@ 123456USherbrooke.ca Fernand.Gobeil@ 123456USherbrooke.ca
                Article
                S0021-9258(21)00100-9 100329
                10.1016/j.jbc.2021.100329
                7949122
                33497625
                3fb7ee9d-b38d-4d2d-83b7-bb89e8118203
                © 2021 The Author(s)

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

                History
                : 19 May 2020
                : 12 January 2021
                Categories
                Research Article

                Biochemistry
                alternative open reading frames (altorfs),coding dna sequence (cds),g-protein-coupled receptors (gpcrs),bradykinin (bk),b2 receptor (b2r),signal transduction,mitogen-activated protein kinases (mapk),altorfs, alternative open reading frames,bifc, bimolecular fluorescence complementation,bk, bradykinin,cdc, coding dna sequence,dab, diaminobenzidine,dmem, dulbecco's modified eagle's medium,egfr, epidermal growth factor receptor,fbs, fetal bovine serum,gpcr, g-protein-coupled receptor,if, immunofluorescence,ihc, immunohistochemistry,ip3, 1,4,5-inositol trisphosphate,kd, kallidin,mapk, mitogen-activated protein kinases,pbs, phosphate-buffered saline,wb, western blot

                Comments

                Comment on this article